Nuvectis Pharma, Inc. Common Stock (NVCT) Stock
NASDAQ · NVCT
20.63
Fundamentals
Market cap
$660.06M
Price / Earnings ratio
-23.3x
Price / Sales ratio
N/A
Price / Book ratio
77.6x
Return on assets
-99.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
NeutralNVCTAugust 19, 2026
Zacks Investment ResearchNeutral
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
NVCT

Zacks Investment Research
Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know
NeutralNVCTJuly 29, 2026
Zacks Investment ResearchNeutral
Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know
NVCT

Zacks Investment Research
Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
NeutralNVCTJuly 8, 2026
Zacks Investment ResearchNeutral
Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
NVCT

Zacks Investment Research
What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now?
NeutralNVCTJuly 1, 2026
Zacks Investment ResearchNeutral
What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now?
NVCT
Technicals
OscillatorsSell5 Indicators
Moving AveragesSell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy3
Strong Buy0
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 8 articles
published over the past 14 days
Latest news

Zacks Investment Research
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
NeutralNVCTAugust 19, 2026
Zacks Investment ResearchNeutral
Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
NVCT

Zacks Investment Research
Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know
NeutralNVCTJuly 29, 2026
Zacks Investment ResearchNeutral
Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know
NVCT

Zacks Investment Research
Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
NeutralNVCTJuly 8, 2026
Zacks Investment ResearchNeutral
Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
NVCT

Zacks Investment Research
What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now?
NeutralNVCTJuly 1, 2026
Zacks Investment ResearchNeutral
What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now?
NVCT

Zacks Investment Research
What Makes Nuvectis Pharma (NVCT) a New Buy Stock
NeutralNVCTJune 26, 2026
Zacks Investment ResearchNeutral
What Makes Nuvectis Pharma (NVCT) a New Buy Stock
NVCT

Reuters
Nuvectis gains two experimental drugs in licensing deal with China's Haisco
NeutralNVCTJune 22, 2026
ReutersNeutral
Nuvectis gains two experimental drugs in licensing deal with China's Haisco
NVCT

InvestorPlace
5 Healthcare Stocks to Buy for 2024
NeutralNVCTApril 2, 2024
InvestorPlaceNeutral
5 Healthcare Stocks to Buy for 2024
NVCT

Zacks Investment Research
3 Best Breakout Stocks Worth Buying for Superlative Returns
NeutralNVCTMay 31, 2023
Zacks Investment ResearchNeutral
3 Best Breakout Stocks Worth Buying for Superlative Returns
NVCT
About Nuvectis Pharma, Inc. Common Stock
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
SectorHealthcare
IndustryBiotechnology
Employees16
CEOMr. Ron Bentsur M.B.A.
IPO DateFeb 4, 2022
HeadquartersFort Lee, NJ
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Ron Bentsur M.B.A. | Co-Founder, Chairman, CEO & President | 1966 |
| Dr. Enrique Poradosu Ph.D. | Co-Founder, Executive VP, Chief Scientific & Business Officer | 1967 |
| Mr. Shay Shemesh | Co-Founder, Executive VP, Chief Development & Operations Officer | 1984 |
| Mr. Michael Carson CPA | Vice President of Finance | 1976 |
Fundamentals
Valuation
Market cap$660.06M
Price-to-sales ratioN/A
Price-to-book value77.59
Price-earnings ratio-23.30
Return on Equity-161.00%
Return on SalesN/A
Return on Assets-99.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-1.31
Income Statement
Average volume221,940
EBITDA$-27.16M
1 year high (52w)$29.28
1 year low (52w)$5.55
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesSell12 Indicators
What the experts say
3 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$36.00
Est return
77.78%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.0 | +10.2 | +5.2 | -12.3 |



